Education
About Us
Working with TipRanks
Follow Us
Eledon Pharmaceuticals (ELDN)
NASDAQ:ELDN
Total Valuation
Eledon Pharmaceuticals has a market cap or net worth of $180.84M. The enterprise value is $164.24M.
Market Cap$180.84M
Enterprise Value$164.24M
Share Statistics
Eledon Pharmaceuticals has 59,881,775 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,881,775
Owned by Insiders22.43%
Owned by Institutions44.36%
Financial Efficiency
Eledon Pharmaceuticals’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -42.99%.
Return on Equity (ROE)-0.30
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-42.99%
Return on Capital Employed (ROCE)-0.43
Revenue Per Employee0.00
Profits Per Employee-1.17M
Employee Count31
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Eledon Pharmaceuticals is -5.66. Eledon Pharmaceuticals’s PEG ratio is -0.31.
PE Ratio-5.66
PS Ratio0.00
PB Ratio1.93
Price to Fair Value1.69
Price to FCF-3.15
Price to Operating Cash Flow-4.05
PEG Ratio-0.31
Income Statement
In the last 12 months, Eledon Pharmaceuticals had revenue of 0.00 and earned -35.32M in profits. Earnings per share was -0.73.
Revenue0.00
Gross Profit0.00
Operating Income-70.58M
Pretax Income-35.75M
Net Income-35.32M
EBITDA-35.39M
Earnings Per Share (EPS)-0.73
Cash Flow
In the last 12 months, operating cash flow was -54.59M and capital expenditures 0.00, giving a free cash flow of -54.59M billion.
Operating Cash Flow-54.59M
Free Cash Flow-54.59M
Free Cash Flow per Share-0.91
Dividends & Yields
Eledon Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.46
52-Week Price Change7.09%
50-Day Moving Average3.17
200-Day Moving Average3.58
Relative Strength Index (RSI)47.63
Average Volume (3m)177.83K
Important Dates
Eledon Pharmaceuticals upcoming earnings date is Nov 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date―
Financial Position
Eledon Pharmaceuticals as a current ratio of 12.42, with Debt / Equity ratio of 0.77%
Current Ratio12.42
Quick Ratio12.42
Debt to Market Cap<0.01
Net Debt to EBITDA0.55
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Eledon Pharmaceuticals has paid 431.00K in taxes.
Income Tax431.00K
Effective Tax Rate-0.01
Enterprise Valuation
Eledon Pharmaceuticals EV to EBITDA ratio is -5.10, with an EV/FCF ratio of -3.82.
EV to Sales0.00
EV to EBITDA-5.10
EV to Free Cash Flow-3.82
EV to Operating Cash Flow-3.82
Balance Sheet
Eledon Pharmaceuticals has $124.88M in cash and marketable securities with $880.00K in debt, giving a net cash position of -$124.00M billion.
Cash & Marketable Securities$124.88M
Total Debt$880.00K
Net Cash-$124.00M
Net Cash Per Share-$2.07
Tangible Book Value Per Share$1.77
Margins
Gross margin is 49.48%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin49.48%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Eledon Pharmaceuticals is $10.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.40
Price Target Upside244.37% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast69.29%